Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
PharmaTher Holdings Ltd ( (TSE:PHRM) ) just unveiled an announcement.
PharmaTher Holdings Ltd. has launched a strategic initiative to seek Health Canada approval and subsequent commercialization of a generic version of semaglutide, the active ingredient in blockbuster diabetes and obesity drugs Ozempic and Wegovy, targeting Canada as one of the first major markets to open to regulated generic competition following the expiry of semaglutide’s regulatory exclusivity. Leveraging its past success in gaining FDA approval and monetizing U.S. rights to ketamine, the company aims to be among the early suppliers of generic semaglutide in Canada with broad dose coverage, a cost-effective sterile injectable manufacturing strategy, and a scalable platform to ensure reliable long-term supply and enable future global partnering opportunities in the fast-growing GLP-1 market.
The most recent analyst rating on (TSE:PHRM) stock is a Sell with a C$0.08 price target. To see the full list of analyst forecasts on PharmaTher Holdings Ltd stock, see the TSE:PHRM Stock Forecast page.
Spark’s Take on TSE:PHRM Stock
According to Spark, TipRanks’ AI Analyst, TSE:PHRM is a Neutral.
Overall score is held down primarily by weak financial performance (pre-revenue, ongoing losses/negative cash flow, shrinking equity) and bearish technical signals (below major moving averages with negative MACD). Positive corporate events (asset sale and program focus) provide some offset, but valuation support is limited given negative earnings and no dividend yield provided.
To see Spark’s full report on TSE:PHRM stock, click here.
More about PharmaTher Holdings Ltd
PharmaTher Holdings Ltd. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing pharmaceutical products and enabling technologies, with particular expertise in injectable drugs and regulatory execution, as evidenced by its prior U.S. FDA approval and partnering success for ketamine.
YTD Price Performance: -14.29%
Average Trading Volume: 71,381
Technical Sentiment Signal: Sell
Current Market Cap: C$8.19M
Learn more about PHRM stock on TipRanks’ Stock Analysis page.